Market Overview

Jefferies Initiates Pfizer With Overweight

Related PFE
The Top 10 Value Stocks In The S&P 500
A Strategy That Beat The S&P 500: Here Are Your 2018 'Dogs Of The Dow'
'Safer' Dividend Challengers Led By Pattern, Tallgrass, Schweitzer & Simon January Target Gains (Seeking Alpha)

Analysts at Jefferies initiated coverage on Pfizer Inc. (NYSE: PFE) with a Overweight rating.

The target price for Pfizer is set to $45.

Pfizer shares have gained 14.57 percent over the past 52 weeks, while the S&P 500 index has surged 7.12 percent in the same period.

Pfizer shares rose 0.06 percent to close at $34.06 yesterday.

Latest Ratings for PFE

Oct 2017BMO CapitalMaintainsOutperform
Sep 2017Morgan StanleyUpgradesEqual-WeightOverweight
Aug 2017BMO CapitalUpgradesMarket PerformOutperform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JefferiesInitiation Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!